Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,580 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cutaneous Clear all

Conditions: Gingival Recession
Interventions: Allograft Material ADM-S, Allograft Material ADM-D; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Wound Closure, Suture Materials
Interventions: Polyglactin 910 (Dyed), Polyglactin 910 (Undyed); Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waynesburg, Pennsylvania

Conditions: Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Akt Inhibitor MK2206, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Skin Cancer
Interventions: Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Dinitrochlorobenzene; Drug
Lead sponsor: The Honolulu Medical Group; Other
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label); Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more

Conditions: Mycosis Fungoides
Interventions: VG712, Mogamulizumab; Drug
Lead sponsor: Virogen Biotechnology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: ganitumab, laboratory biomarker analysis, pharmacological study, biopsy; Biological · Other · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cutaneous T Cell Lymphoma
Interventions: APR-TD011 (RLF-TD011); Combination Product
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: arsenic trioxide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 17 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
Interventions: Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 13 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Genetically Engineered Lymphocyte Therapy; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer, Penile Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Vaginal Squamous Cell Carcinoma, Urethral Squamous Cell Carcinoma
Interventions: EVOLVE104; Drug
Lead sponsor: EvolveImmune United, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 10 more

Conditions: Anterior Cruciate Ligament Reconstruction, Medial Patellofemoral Ligament Reconstruction
Interventions: Bupivacaine, Dexamethasone in Adductor Canal Block, Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 8 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Wound Healing
Interventions: TolaSure Topical Gel; Drug
Lead sponsor: BioMendics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma
Interventions: Dabrafenib, Trametinib, Trametinib placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more

Conditions: Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 513 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cutaneous Melanoma
Interventions: Not listed
Lead sponsor: Castle Biosciences Incorporated; Industry
Eligibility: 16 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia • Louisville, Kentucky • St Louis, Missouri

Conditions: Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions: Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Adult
Interventions: Collagen Matrix Skin Prick Test Device; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Monroeville, Pennsylvania

Conditions: Large Cell Lymphoma
Interventions: SGN-30; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 9 more

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
Interventions: Not listed
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Gingival Augmentation and Root Coverage With Superficial and Deep Cut Acellular Dermal Matrices

Dyed vs. Undyed Polyglactin Sutures in Cutaneous Surgery

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

A Study of VG712 in Patients With Mycosis Fungoides

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Anterior Femoral and Adductor Canal Nerve Blocks in Peds Knees

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Duke Autoimmunity in Pregnancy Registry

5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

This Study Evaluates Skin Response Following Application of a Collagen-based Material in Healthy Adult Volunteers Using a Standardized Skin Prick Test. Skin Responses Will be Assessed at Multiple Time Points Following Application, and the Study is Intended to Evaluate Dermal Safety.

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab